Trial Profile
A Phase 3 Multicenter, Randomized, Double Blind, Parallel Group Study Followed by Dose Blind Period and Open Label Follow Up to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Dec 2022
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms CIMPASI-1
- Sponsors UCB
- 13 Dec 2022 Results of pooled analysis from CIMPASI-1 and CIMPASI-, assessing 3-year quality of life outcomes for patients treated with Certolizumab Pegol, published in the Dermatology and Therapy
- 03 Dec 2021 Results of pooled analysis from (CIMPASI-1 AND CIMPASI-2) studies presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 11 Jul 2020 Results of pooled analysis from CIMPASI-1and CIMPASI-2, assessing three-year efficacy of Certolizumab-pegol in Plaque-psoriasis, published in the British Journal of Dermatology